Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia

European Journal of Pharmacology

Volumn 639, Issue 1-3, 2010, Pages 59-66

  Chaki, Shigeyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antipsychotic; MGlu2 3 receptor; MGlu2 receptor; MGlu3 receptor; Schizophrenia

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; CLOZAPINE; EGLUMETAD; GLUTAMIC ACID; HALOPERIDOL; LY 314582; LY 487379; LY 566332; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; MG S0008; MG S0028; MGS 0008; MGS 0028; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OLANZAPINE; PLACEBO; RISPERIDONE; SEROTONIN 2A AGONIST; UNCLASSIFIED DRUG; VOLINANSERIN; AMINO ACID RECEPTOR STIMULATING AGENT; METABOTROPIC RECEPTOR;

CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITION; DOPAMINE RELEASE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SYNTHESIS; EXPERIMENTAL MODEL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOCOMOTION; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TRANQUILIZING ACTIVITY; TREATMENT DURATION; AGONISTS; ANIMAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SYNAPTIC TRANSMISSION; SYNTHESIS;

ANIMALS; ANTIPSYCHOTIC AGENTS; EXCITATORY AMINO ACID AGONISTS; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 77953620136     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.12.041     Document Type: Review

References (89)

1. Adams B.W., Moghaddam B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol. Psychiatry 2001, 50:750-757.
2. Akil M., Pierri J.N., Whitehead R.E., Edgar C.L., Mohila C., Sampson A.R., Lewis D.A. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am. J. Psychiatry 1999, 156:1580-1589.
3. Aronica E., Gorter J.A., Ijlst-Keizers H., Rozemuller A.J., Yankaya B., Leenstra S., Troost D. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur. J. Neurosci. 2003, 17:2106-2118.
4. Benneyworth M.A., Xiang Z., Smith R.L., Garcia E.E., Conn P.J., Sanders-Bush E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol. Pharmacol. 2007, 72:477-484.
5. Bond A., Jones N.M., Hicks C.A., Whiffin G.M., Ward M.A., O'Neill M.F., Kingston A.E., Monn J.A., Ornstein P.L., Schoepp D.D., Lodge D., O'Neill M.J. Neuroprotective effects of LY379268, a selective mGluR2/3 receptor agonist: investigation into possible mechanism of action in vivo. J. Pharmacol. Exp. Ther. 2000, 294:800-809.
6. Brown E.M., Gamba G., Ricardi D., Lombardi M., Butters R., Kifor O., Sun A., Hediger M.A., Lytton J., Herbert S.C. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 1993, 366:575-580.
7. Brozoski T.J., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979, 205:929-932.
8. Bruno V., Battaglia G., Casabona G., Copani A., Caciagli F., Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J. Neurosci. 1998, 18:9594-9600.
9. Calcagno E., Carli M., Baviera M., Invernizzi R.W. Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade. J. Neurochem. 2009, 108:521-532.
10. Cartmell J., Monn J., Schoepp D.D. Attenuation of specific PCP-evoked behaviors by the potent mGluR2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology 2000, 148:423-429.
11. Cartmell J., Perry K.W., Salhoff C.R., Monn J.A., Schoepp D.D. Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 2001, 40:847-855.
12. Chaki S., Yoshikawa R., Okuyama S. Group II metabotropic glutamate receptor-mediated regulation of dopamine release from slices of rat nucleus accumbens. Neurosci. Lett. 2006, 404:182-186.
13. Chen Q., He G., Chen Q., Wu S., Xu Y., Feng G., Li Y., Wang L., He L. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr. Res. 2005, 73:21-26.
14. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Ann. Rev. Pharmacol. Toxicol. 1997, 37:205-237.
15. Conn P.J., Lindsley C.W., Jones C.K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci. 2009, 30:25-31.
16. Corti C., Crepaldi L., Mion S., Roth A.L., Xuereb J.H., Ferraguti F. Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol. Psychiatry 2007, 62:747-755.
17. Coyle J.T., Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 2004, 174:32-38.
18. Dudkin K.N., Kruchinin V.K., Chueva I.V. Neurophysiological correlates of delayed visual differentiation tasks in monkeys: the effects of the site of intracortical blockade of NMDA receptors. Neurosci. Behav. Physiol. 2001, 31:207-218.
19. Dunayevich E., Erickson J., Levine L., Landbloom R., Schoepp D.D., Tollefson G.D. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008, 33:1603-1610.
20. Egan M.F., Straub R.E., Goldberg T.E., Yakub I., Callicott J.H., Hariri A.R., Mattay V.S., Bertolino A., Hyde T.M., Shannon-Weickert C., Akil M., Crook J., Vakkalanka R.K., Balkissoon R., Gibbs R.A., Kleinman J.E., Weinberger D.R. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:12604-12609.
21. Faustman W.O., Bardgett M., Faull K.F., Pfefferbaum A., Csernansky J.G. Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Biol. Psychiatry 1999, 45:68-75.
22. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4, 6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 2008, 326:209-217.
23. Fricker A.C., Mok M.H., de la Flor R., Shah A.J., Woolley M., Dawson L.A., Kew J.N. Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology 2009, 56:1060-1067.
24. Fujii Y., Shibata H., Kikuta R., Makino C., Tani A., Hirata N., Shibata A., Ninomiya H., Tashiro N., Fukumaki Y. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr. Genet. 2003, 13:71-76.
25. Galici R., Echemendia N.G., Rodriguez A.L., Conn P.J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 2005, 315:1181-1187.
26. Gewirtz J.C., Marek G.J. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 2000, 23:569-576.
27. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001, 156:117-154.
28. Ghose S., Gleason K.A., Potts B.W., Lewis-Amezcua K., Tamminga C.A. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?. Am. J. Psychiatry 2009, 166:812-820.
29. Gleason S.D., Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 1997, 129:79-84.
30. González-Maeso J., Weisstaub N.V., Zhou M., Chan P., Ivic L., Ang R., Lira A., Bradley-Moore M., Ge Y., Zhou Q., Sealfon S.C., Gingrich J.A. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007, 53:439-452.
31. González-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., López-Giménez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G., Gingrich J.A., Filizola M., Meana J.J., Sealfon S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452:93-97.
32. Gozzi A., Large C.H., Schwarz A., Bertani S., Crestan V., Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 2008, 33:1690-1703.
33. Greenslade R.G., Mitchell S.N. Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4, 6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell. Neuropharmacology 2004, 47:1-8.
34. Grillon C., Cordova J., Levine L.R., Morgan C.A. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 2003, 168:446-454.
35. Harich S., Gross G., Bespalov A. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl) 2007, 192:511-519.
36. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., Kallman M.J. LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology 1997, 36:1511-1516.
37. Henry S.A., Lehmann-Masten V., Gasparini F., Geyer M.A., Markou A. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002, 43:1199-1209.
38. Higgins G.A., Ballard T.M., Kew J.N., Richards J.G., Kemp J.A., Adam G., Woltering T., Nakanishi S., Mutel V. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 2004, 46:907-917.
39. Holcomb H.H., Lahti A.C., Medoff D.R., Cullen T., Tamminga C.A. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 2005, 30:2275-2282.
40. Imre G., Fokkema D.S., Ter Horst G.J. Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats. Eur. J. Pharmacol. 2006, 544:77-81.
41. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
42. Jones C.K., Eberle E.L., Peters S.C., Monn J.A., Shannon H.E. Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing. Neuropharmacology 2005, 49:206-218.
43. Karasawa J., Yoshimizu T., Chaki S. A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell. Neurosci. Lett. 2006, 393:127-130.
44. Karasawa J., Hashimoto K., Chaki S. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav. Brain Res. 2008, 186:78-83.
45. Kaupmann K., Huggel K., Heid J., Flor P.J., Bischoff S., Mickel S.J., McMaster G., Angst C., Bittiger H., Froestl W., Bettler B. Expression cloning of GABAB receptors uncovers similarity to metabotropic glutamate receptors. Nature 1997, 386:239-246.
46. Kellner M., Muhtz C., Stark K., Yassouridis A., Arlt J., Wiedemann K. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results. Psychopharmacology (Berl) 2005, 179:310-315.
47. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmüller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 1980, 20:379-382.
48. Kim H.S., Park I.S., Park W.K. NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in mice. Life Sci. 1998, 63:2305-2311.
49. Klodzinska A., Bijak M., Chojnacka-Wojcik E., Kroczka B., Swiader M., Czuczwar S.J., Pilc A. Roles of group II metabotropic glutamate receptors in modulation of seizure activity. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 361:283-288.
50. Konieczny J., Ossowska K., Wolfarth S., Plic A. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn Schmiedeberg's Arch. Pharmacol. 1998, 358:500-502.
51. Krystal J.H., Abi-Saab W., Perry E., D'Souza D.C., Liu N., Gueorguieva R., McDougall L., Hunsberger T., Belger A., Levine L., Breier A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005, 179:303-309.
52. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
53. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001, 25:455-467.
54. Lewis D.A., Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat. Med. 2006, 12:1016-1022.
55. Lewis D.A., Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch. Neurol. 2006, 63:1372-1376.
56. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
57. Marek G.J., Wright R.A., Schoepp D.D., Monn J.A., Aghajanian G.K. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther. 2000, 292:76-87.
58. Marek G.J., Wright R.A., Gewirtz J.C., Schoepp D.D. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience 2001, 105:379-392.
59. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic receptor agonists in rats. Science 1998, 281:1349-1352.
60. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
61. Molinaro G., Traficante A., Riozzi B., Di Menna L., Curto M., Pallottino S., Nicoletti F., Bruno V., Battaglia G. Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-HT2A serotonin receptors in the frontal cortex of living mice. Mol. Pharmacol. 2009, 76:379-387.
62. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992, 258:597-603.
63. Nakanishi S., Masu M. Molecular diversity and functions of glutamate receptors. Ann. Rev. Biophys. Biomol. Struct. 1994, 23:319-348.
64. Nakazato A., Kumagai T., Sakagami K., Yoshikawa R., Suzuki Y., Chaki S., Ito H., Taguchi T., Nakanishi S., Okuyama S. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2, 6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists. J. Med. Chem. 2000, 43:4893-4909.
65. Neale J.H., Bzdega T., Wroblewska B. N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J. Neurochem. 2000, 75:443-452.
66. Neale J.H., Olszewski R.T., Gehl L.M., Wroblewska B., Bzdega T. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol. Sci. 2005, 26:477-484.
67. Neki A., Ohishi H., Kaneko T., Shigemoto R., Nakanishi S., Mizuno N. Pre- and postsynaptic localization of a metabotropic glutamate receptor, mGluR2, in the rat brain: an immunohistochemical study with a monoclonal antibody. Neurosci. Lett. 1996, 202:197-200.
68. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Melson A.K., Hershey T., Craft S., Olney J.W. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20:106-118.
69. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 1993, 53:1009-1018.
70. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J. Comp. Neurol. 1993, 335:252-266.
71. Olszewski R.T., Wegorzewska M.M., Monteiro A.C., Krolikowski K.A., Zhou J., Kozikowski A.P., Long K., Mastropaolo J., Deutsch S.I., Neale J.H. Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol. Psychiatry 2008, 63:86-91.
72. Palucha A., Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol. Ther. 2007, 115:116-147.
73. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
74. Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and fuctions. J. Neurochem. 1992, 58:1184-1186.
75. Rorick-Kehn L.M., Johnson B.G., Knitowski K.M., Salhoff C.R., Witkin J.M., Perry K.W., Griffey K.I., Tizzano J.P., Monn J.A., McKinzie D.L., Schoepp D.D. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 2007, 193:121-136.
76. Sartorius L.J., Weinberger D.R., Hyde T.M., Harrison P.J., Kleinman J.E., Lipska B.K. Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology 2008, 33:2626-2634.
77. Sawaguchi T., Goldman-Rakic P.S. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J. Neurophysiol. 1994, 71:515-528.
78. Schlumberger C., Schäfer D., Barberi C., Morè L., Nagel J., Pietraszek M., Schmidt W.J., Danysz W. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav. Pharmacol. 2009, 20:56-66.
79. Schoepp D.D., Conn P.J. Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol. Sci. 1993, 14:13-20.
80. Schoepp D.D., Wright R.A., Levine L.R., Gaydos B., Potter W.Z. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003, 6:189-197.
81. Shimazaki T., Kaku A., Chaki S. Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats. Eur. J. Pharmacol. 2007, 575:94-97.
82. Shirayama Y., Chaki S. Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Curr. Neuropharmacol. 2006, 4:277-291.
83. Takahashi K., Tsuchida K., Tanabe Y., Masu M., Nakanishi S. Role of the large extracellular domain of metabotropic glutamate receptors in agonist selectivity determination. J. Biol. Chem. 1993, 268:19341-19345.
84. Takamori K., Hirota S., Chaki S., Tanaka M. Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MGS0028 on conditioned avoidance responses in the rat. Life Sci. 2003, 73:1721-1728.
85. Tanabe Y., Masu M., Ishii T., Shigemoto R., Nakanishi S. A family of metabotropic glutamate receptors. Neuron 1992, 8:169-179.
86. Tanabe Y., Nomura A., Masu M., Shigemoto R., Mizuno N., Shigetada N. Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J. Neurosci. 1993, 13:1372-1378.
87. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., Coyle J.T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 1995, 52:829-836.
88. Vandergriff J., Rasmussen K. The selective mGluR2/3 receptor antagonist LY354740 attenuates morphine- withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology 1999, 38:217-222.
89. Volk D.W., Austin M.C., Pierri J.N., Sampson A.R., Lewis D.A. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 2000, 57:237-245.